Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AJAY SOOD

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1821220856
CMS profile
1397458
Location
ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,659.67

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Piramal Imaging Limited $1,375.00 1
EISAI INC. $200.79 2
Coloplast Corp $43.93 1
Genentech, Inc. $39.95 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AJAY SOOD

NPI 1821220856 · CMS profile ID 1397458

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ELK GROVE VILLAGE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821220856?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AJAY SOOD, NPI 1821220856, CMS profile ID 1397458. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821220856?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AJAY SOOD, NPI 1821220856, CMS profile ID 1397458. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821220856?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AJAY SOOD, NPI 1821220856, CMS profile ID 1397458, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1821220856?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $1,659.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Coloplast Corp $43.9309/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696983645 CMS
EISAI INC. $125.0007/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699984347 CMS
Eisai Inc. $75.7907/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698081057 CMS
Genentech, Inc. $39.9504/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681170446 CMS
Piramal Imaging Limited $1,375.0001/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707744353 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,659.67 5
PY2025 $4,584.98 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2020 Recipient $175.00 1
PY2020 Principal investigator $279,161.56 110
PY2019 Principal investigator $707,165.54 144

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

144 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $4,405.50 12/17/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681104685
Principal investigator 1 Genentech, Inc. $17,964.90 12/12/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681118833
Principal investigator 1 Genentech, Inc. $465.00 12/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681075415
Principal investigator 1 Genentech, Inc. $10,036.00 12/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681076409
Principal investigator 1 Genentech, Inc. $500.00 12/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681107283
Principal investigator 1 Genentech, Inc. $400.00 12/05/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681113801
Principal investigator 1 Eisai Inc. $2,125.00 11/26/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544801
Principal investigator 1 Eisai Inc. $1,175.00 11/26/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544803
Principal investigator 1 Eisai Inc. $1,175.00 11/26/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544805
Principal investigator 1 Eisai Inc. $2,125.00 11/26/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544807
Principal investigator 1 Eisai Inc. $1,175.00 11/26/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544809
Principal investigator 1 Genentech, Inc. $21,324.60 11/15/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681099209
Principal investigator 1 Genentech, Inc. $200.00 11/15/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681111211
Principal investigator 1 Genentech, Inc. $4,450.00 11/07/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681111989
Principal investigator 1 Genentech, Inc. $450.00 11/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681101719
Principal investigator 1 Genentech, Inc. $10,035.72 11/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681110081
Principal investigator 1 Eisai Inc. $3,590.00 10/31/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544785
Principal investigator 1 Eisai Inc. $2,000.00 10/31/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544787
Principal investigator 1 Eisai Inc. $3,802.00 10/31/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544789
Principal investigator 1 Eisai Inc. $3,585.00 10/31/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544791
Principal investigator 1 Eisai Inc. $2,000.00 10/31/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544793
Principal investigator 1 Eisai Inc. $3,368.00 10/31/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544795
Principal investigator 1 Eisai Inc. $3,585.00 10/31/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544797
Principal investigator 1 Eisai Inc. $2,000.00 10/31/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544799
Principal investigator 1 Genentech, Inc. $14,454.00 10/24/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681067511
Principal investigator 1 Genentech, Inc. $2,000.00 10/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681099115
Principal investigator 1 Genentech, Inc. $1,050.00 10/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681108439
Principal investigator 1 Genentech, Inc. $200.00 10/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681108919
Principal investigator 1 Eisai Inc. $1,175.00 10/01/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544659
Principal investigator 1 Genentech, Inc. $28,179.90 10/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681114731
Principal investigator 1 Genentech, Inc. $300.00 09/16/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681076653
Principal investigator 1 Genentech, Inc. $155.00 09/10/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681112871
Principal investigator 1 Genentech, Inc. $500.00 09/03/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681069045
Principal investigator 1 Genentech, Inc. $500.00 09/03/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681098625
Principal investigator 1 Eisai Inc. $2,323.00 08/15/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544661
Principal investigator 1 Genentech, Inc. $1,500.00 08/09/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681097707
Principal investigator 1 Genentech, Inc. $100.00 08/09/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681100159
Principal investigator 1 Genentech, Inc. $11,510.10 07/25/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681071511
Principal investigator 1 Genentech, Inc. $500.00 07/25/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681072097
Principal investigator 1 Genentech, Inc. $500.00 07/25/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681096357
Principal investigator 1 Genentech, Inc. $200.00 07/25/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681117159
Principal investigator 1 Eisai Inc. $1,505.00 07/09/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544673
Principal investigator 1 Genentech, Inc. $14,151.60 07/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681099949
Principal investigator 1 Eisai Inc. $1,820.00 05/30/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544663
Principal investigator 1 Eisai Inc. $1,175.00 05/30/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544665
Principal investigator 1 Eisai Inc. $1,850.00 05/30/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544667
Principal investigator 1 Eisai Inc. $1,985.00 05/30/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544669
Principal investigator 1 Eisai Inc. $1,175.00 05/30/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544671
Principal investigator 1 Genentech, Inc. $33,029.10 05/16/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681088787
Principal investigator 1 Genentech, Inc. $400.00 05/16/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681095835
Principal investigator 1 Genentech, Inc. $111.87 05/09/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681080183
Principal investigator 1 Genentech, Inc. $111.87 05/09/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681088315
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544675
Principal investigator 1 Eisai Inc. $894.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544677
Principal investigator 1 Eisai Inc. $1,874.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544679
Principal investigator 1 Eisai Inc. $516.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544681
Principal investigator 1 Eisai Inc. $1,686.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544683
Principal investigator 1 Eisai Inc. $385.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544685
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544687
Principal investigator 1 Eisai Inc. $894.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544689
Principal investigator 1 Eisai Inc. $1,874.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544691
Principal investigator 1 Eisai Inc. $516.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544693
Principal investigator 1 Eisai Inc. $385.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544695
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544697
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544699
Principal investigator 1 Eisai Inc. $1,686.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544701
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544703
Principal investigator 1 Eisai Inc. $894.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544705
Principal investigator 1 Eisai Inc. $1,874.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544707
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544709
Principal investigator 1 Eisai Inc. $516.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544711
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544713
Principal investigator 1 Eisai Inc. $385.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544715
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544717
Principal investigator 1 Eisai Inc. $894.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544719
Principal investigator 1 Eisai Inc. $2,000.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544721
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544723
Principal investigator 1 Eisai Inc. $1,175.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544725
Principal investigator 1 Eisai Inc. $1,874.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544727
Principal investigator 1 Eisai Inc. $2,000.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544729
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544731
Principal investigator 1 Eisai Inc. $2,323.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544733
Principal investigator 1 Eisai Inc. $3,368.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544735
Principal investigator 1 Eisai Inc. $1,175.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544737
Principal investigator 1 Eisai Inc. $1,175.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544739
Principal investigator 1 Eisai Inc. $2,000.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544741
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544743
Principal investigator 1 Eisai Inc. $2,794.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544745
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544747
Principal investigator 1 Eisai Inc. $2,000.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544749
Principal investigator 1 Eisai Inc. $3,802.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544751
Principal investigator 1 Eisai Inc. $516.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544753
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544755
Principal investigator 1 Eisai Inc. $385.00 05/07/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544757
Principal investigator 1 Genentech, Inc. $350.00 05/03/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681083291
Principal investigator 1 Genentech, Inc. $48.00 05/02/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681088317
Principal investigator 1 Eli Lilly and Company $5,758.01 04/25/2019 Non-covered Recipient Entity
YALE UNIVERSITY
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654299129
Principal investigator 1 Genentech, Inc. $1,865.70 04/23/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681095067
Principal investigator 1 Genentech, Inc. $300.00 04/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681092953
Principal investigator 1 Eisai Inc. $3,802.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544633
Principal investigator 1 Eisai Inc. $1,505.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544635
Principal investigator 1 Eisai Inc. $1,686.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544637
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544639
Principal investigator 1 Eisai Inc. $1,686.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544641
Principal investigator 1 Eisai Inc. $894.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544643
Principal investigator 1 Eisai Inc. $1,874.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544645
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544647
Principal investigator 1 Eisai Inc. $516.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544649
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544651
Principal investigator 1 Eisai Inc. $2,000.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544653
Principal investigator 1 Eisai Inc. $1,686.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544655
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544657
Principal investigator 1 Eisai Inc. $385.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544759
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544761
Principal investigator 1 Eisai Inc. $2,000.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544763
Principal investigator 1 Eisai Inc. $1,686.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544765
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544767
Principal investigator 1 Eisai Inc. $894.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544769
Principal investigator 1 Eisai Inc. $1,874.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544771
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544773
Principal investigator 1 Eisai Inc. $516.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544775
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544777
Principal investigator 1 Eisai Inc. $3,802.00 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544779
Principal investigator 1 Eisai Inc. $809.10 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544781
Principal investigator 1 Eisai Inc. $589.40 04/02/2019 Non-covered Recipient Entity
AMITA HEALTH ACCOUNTABLE CARE ORGANIZATION, LLC
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702544783
Principal investigator 1 Genentech, Inc. $75.00 04/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681081061
Principal investigator 1 Genentech, Inc. $48.00 04/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681092951
Principal investigator 1 Genentech, Inc. $7,500.00 03/25/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY FOR MODERATE AD No dispute reported 06/30/2026 681087691
Principal investigator 1 Genentech, Inc. $7,283.70 03/18/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681092197
Principal investigator 1 Genentech, Inc. $2,338.00 03/08/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681086705
Principal investigator 1 Genentech, Inc. $500.00 03/08/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681095065
Principal investigator 1 Eli Lilly and Company $280,790.53 03/05/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654287635
Principal investigator 1 Genentech, Inc. $9,625.50 03/01/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681079869
Principal investigator 1 Genentech, Inc. $450.00 02/19/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681087265
Principal investigator 1 Genentech, Inc. $1,060.00 02/19/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681088103
Principal investigator 1 Genentech, Inc. $16,695.00 02/19/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681088105
Principal investigator 1 Genentech, Inc. $26,871.30 02/06/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681086271
Principal investigator 1 Genentech, Inc. $111.87 02/04/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681090605
Principal investigator 1 Genentech, Inc. $500.00 02/04/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681094275
Principal investigator 1 Eli Lilly and Company $150.00 01/31/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS MEDICAL CENTER - NEUROSCIENCE RESEARCH INSTITUTE
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654287103
Principal investigator 1 Eli Lilly and Company $1,264.97 01/16/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 654287663
Principal investigator 1 Genentech, Inc. $300.00 01/11/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681091457
Principal investigator 1 Genentech, Inc. $865.00 01/03/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681087263
Principal investigator 1 Genentech, Inc. $35,196.30 01/02/2019 Non-covered Recipient Entity
ALEXIAN BROTHERS HOSPITAL NETWORK
PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD No dispute reported 06/30/2026 681090603